Samsung Bioepis acquires product approval of ‘Samfenet,’ Herceptin biosimilar

Published: 2017-11-10 16:28:00
Updated: 2017-11-10 14:09:18

‘SB3(product name: Samfenet, generic name: trastuzumab),’ a Samsung Bioepis’ cancer therapy biosimilar, acquire product approval from the Ministry of Food and Drug Safety on the 8th.

Samfenet is a biosimilar of ‘Herceptin(trastuzumab),’ a antibody for various cancers, such as metastatic breast c...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean




Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.